| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT05755386 Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN |
Trial sites expanded: 127 -> 130 locations |
| 2026-06-02 | NCT04557462 A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT04557462 A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of… |
Enrollment reduced: 540 -> 448 participants |
| 2026-06-02 | NCT04557462 A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of… |
Trial sites reduced: 161 -> 155 locations |
| 2026-05-28 | NCT06517758 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared… |
Trial sites expanded: 113 -> 124 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03955445 | Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN | C3 Glomerulopathy | Recruiting |
| NCT06934967 | Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric… | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Recruiting |
| NCT05935215 | Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment… | Atypical Hemolytic Uremic Syndrome | Recruiting |
| NCT06517758 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared… | Generalized Myasthenia Gravis | Recruiting |
| NCT04817618 | Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | C3G | Recruiting |
| NCT05755386 | Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN | IC-MPGN | Recruiting |
| NCT06994845 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in… | Primary Immunoglobulin A Nephropathy (IgAN) | Recruiting |
| NCT05795140 | Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants… | Atypical Hemolytic Uremic Syndrome | Recruiting |
| NCT04747613 | Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal… | Paroxysmal Nocturnal Hemoglobinuria | Active, Not Recruiting |
| NCT04557462 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of… | Primary IgA Nephropathy | Active, Not Recruiting |
| Phase 2 | |||
| NCT06797518 | Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of… | Glomerulonephritis, IGA | Recruiting |
| NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class… | Lupus Nephritis | Recruiting |
| NCT06388941 | Iptacopan in Patients With ANCA Associated Vasculitis | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Active, Not Recruiting |
| Not specified | |||
| NCT06931691 | A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult… | Paroxysmal Nocturnal Hemoglobinuria | Recruiting |
| NCT07347990 | Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated… | Thrombotic Microangiopathy | Not Yet Recruiting |